Back to Search Start Over

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.

Authors :
Okita K
Izumi N
Ikeda K
Osaki Y
Numata K
Ikeda M
Kokudo N
Imanaka K
Nishiguchi S
Kondo S
Nishigaki Y
Shiomi S
Ueshima K
Isoda N
Karino Y
Kudo M
Tanaka K
Kaneko S
Moriwaki H
Makuuchi M
Okusaka T
Hayashi N
Ohashi Y
Kumada H
Source :
Journal of gastroenterology [J Gastroenterol] 2015 Jun; Vol. 50 (6), pp. 667-74. Date of Electronic Publication: 2014 Sep 11.
Publication Year :
2015

Abstract

Background: This study examined the effects of peretinoin, an acyclic retinoid, on the survival of patients with hepatitis C virus-related hepatocellular carcinoma (HCC) who had completed curative therapy and participated in a randomized, placebo-controlled trial.<br />Methods: This study was an investigator-initiated retrospective cohort study. Subjects were all patients who were administered the investigational drug (peretinoin 600 mg/day, peretinoin 300 mg/day, or placebo) in the randomized trial. Survivals between the groups were compared using the log-rank test, and hazard ratios were estimated by Cox regression.<br />Results: Survey data were collected from all patients (n = 392) who participated in the randomized trial, all of whom were then divided into the peretinoin 600 mg/day (n = 132), peretinoin 300 mg/day (n = 131), and placebo (n = 129) groups. At the median follow-up of 4.9 years, 5-year cumulative survival rates for patients in the 600 mg/day, 300 mg/day, and placebo groups were 73.9, 56.8, and 64.3 %, respectively. Comparison of overall survival among patients classified as Child-Pugh A revealed that survival of the 600 mg/day group (n = 105) was significantly longer than that of the placebo group (n = 108) (hazard ratio 0.575, 95 % CI 0.341-0.967; P = 0.0347).<br />Conclusions: Administration of 600 mg/day peretinoin to patients with hepatitis C virus-related HCC who have completed curative therapy may improve survival for those classified as Child-Pugh A, for whom liver function is relatively stable.

Details

Language :
English
ISSN :
1435-5922
Volume :
50
Issue :
6
Database :
MEDLINE
Journal :
Journal of gastroenterology
Publication Type :
Academic Journal
Accession number :
25209978
Full Text :
https://doi.org/10.1007/s00535-014-0996-1